Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis

References

• Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 2006;70(8):1403–12.
   PubMed Web of Science ®Google Scholar
• Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A, et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM. 2001;94(1):19–26.
   PubMed Web of Science ®Google Scholar
• Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus–what’s hot and what's not!. Rheumatology (Oxford). 2009;48(4):332–41.
   PubMed Web of Science ®Google Scholar
• Steinberg AD. The treatment of lupus nephritis. Kidney Int. 1986; 30(5):769–87.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA IIIrd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549–57.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA IIIrd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741–5.
   PubMed Web of Science ®Google Scholar
• Ntali S, Bertsias G, Boumpas DT. Cyclophosphamide and lupus nephritis: when, how, for how long?. Clin Rev Allergy Immunol. 2011;40(3):181–91.
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–62.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.
   PubMed Web of Science ®Google Scholar
• Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology. 2005;10(5):504–10.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103–12.
   PubMed Web of Science ®Google Scholar
• Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007; 2(5):968–75.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Chapter 12: Lupus nephritis. Kidney Int Suppl. 2012;2:221–32.
   Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012; 71(11):1771–82.
   PubMed Web of Science ®Google Scholar
• Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19:1281–9.
   PubMed Web of Science ®Google Scholar
• Chen W, Tang X, Liu Q, Fu P, Liu F, Liao Y, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235–44.
   PubMed Web of Science ®Google Scholar
• Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4):1467–72.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Hiromura K, Sakurai N, Matsumoto T, Ikeuchi H, Maeshima A, et al. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol. 2011;21(3):282–9.
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+ IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001–10.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40.
   PubMed Web of Science ®Google Scholar
• Li H, Shi X, Shen H, Li X, Wang H, Xu G, et al. Tacrolimus versus intravenous pulse cyclophosphamide therapy in chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Clinical therapeutics. 2012; 34(5):1112–20.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64(11):3660–5.
   PubMed Web of Science ®Google Scholar
• Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59(6):2156–63.
   PubMed Web of Science ®Google Scholar
• Holdsworth SR, Kitching AR, Tipping PG. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 1999;55(4):1198–216.
   PubMed Web of Science ®Google Scholar
• Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol. 1999;10(6):1366–80.
   PubMed Web of Science ®Google Scholar
• Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update. Drugs Today (Barc). 2009;45(7):521–32.
   PubMed Web of Science ®Google Scholar
• Kagawa H, Hiromasa T, Hara T, Takaki A, Yamanaka R, Sada KE, Makino H. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol. 2012;16(5):760–6.
   PubMed Web of Science ®Google Scholar
• Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus. 2012;21(13):1444–9.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009:681482.
   PubMedGoogle Scholar
• Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?—A mini-review. Braz J Infect Dis. 2006;10(2):132–8.
   PubMedGoogle Scholar
• Falk RJ, Schur PH, Appel GB. Indications for renal biopsy in patients with lupus nephritis. In: UpToDate, Sheridan AM, editor. Waltham: MA; 2009.
   Google Scholar
• Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol. 2000;27(12):2822–6.
   PubMed Web of Science ®Google Scholar